Treatments for Adrenal Cortical Carcinoma

 Treatments for Adrenal Cortical Carcinoma

Drugs used to treat Adrenal Cortical Carcinoma

 

Lysodren

Mitotane

What is Adrenal Cortical Carcinoma?

 

Adrenal Cortical Carcinoma (ACC) is a rare and aggressive cancer originating in the adrenal cortex, the outer layer of the adrenal glands, which are located on top of the kidneys. This cancer can produce hormones and affects hormone regulation in the body, often resulting in significant symptoms. ACC most frequently occurs in adults, but it can also develop in children. Here’s a detailed breakdown of ACC:

 

1. Epidemiology and Risk Factors

   - Incidence: ACC is extremely rare, with an estimated incidence of 1–2 cases per million people annually.

   - Demographics: It can occur at any age but peaks in early childhood and between the ages of 40 and 50.

   - Gender: Slightly more common in women than men.

   - Risk Factors: Genetic syndromes like Li-Fraumeni syndrome, Beckwith-Wiedemann syndrome, Lynch syndrome, and multiple endocrine neoplasia (MEN1) increase the risk. No definitive environmental risk factors have been identified, though smoking may have some association.

 

2. Symptoms and Signs

   ACC symptoms vary depending on whether the tumor is functional (producing hormones) or non-functional:

  

   - Functional Tumors (Hormone-Secreting):

     - Cushing's Syndrome: Excess cortisol production can cause weight gain, high blood pressure, diabetes, muscle weakness, and mood changes.

     - Virilization: Overproduction of androgens (male hormones) can lead to abnormal hair growth, deepened voice, and irregular menstrual cycles in women or early puberty in children.

     - Feminization: Overproduction of estrogens (female hormones) can cause gynecomastia (breast growth) in men and early signs of puberty in young children.

   - Non-functional Tumors:

     - Symptoms may result from the tumor’s physical presence, including abdominal pain, back pain, a palpable mass, weight loss, and loss of appetite.

 

3. Diagnosis

   Diagnosis involves a combination of clinical, biochemical, and imaging studies:

 

   - Hormonal Testing: Blood and urine tests to measure cortisol, aldosterone, androgen, and estrogen levels to identify hormone-secreting tumors.

   - Imaging:

     - CT Scan: Detailed images to determine tumor size, shape, and any spread.

     - MRI: Useful for viewing adrenal masses and to differentiate ACC from benign adrenal adenomas.

     - PET Scan: Helpful in staging and assessing metastatic disease.

   - Biopsy: Rarely performed due to the risk of spreading cancerous cells, but sometimes used if the diagnosis is uncertain.

 

4. Staging

   ACC is staged from I to IV, with the staging depending on tumor size, invasion into surrounding tissues, and the extent of metastasis:

   - Stage I: Tumor is ≤5 cm and confined to the adrenal gland.

   - Stage II: Tumor is >5 cm but still confined to the adrenal gland.

   - Stage III: Tumor has spread to surrounding tissues or nearby lymph nodes.

   - Stage IV: Cancer has metastasized to distant organs, such as the liver, lungs, or bones.

 

5. Treatment Options

   - Surgery: The mainstay treatment for localized ACC. Complete surgical resection (adrenalectomy) is often the goal.

   - Mitotane: An adrenolytic drug used specifically for ACC; it reduces adrenal hormone production and can help control symptoms in advanced cases.

   - Chemotherapy: Used for inoperable or metastatic ACC, usually in combination with mitotane.

   - Radiation Therapy: Occasionally used after surgery to reduce the risk of recurrence or for symptom control in advanced cases.

   - Hormone Therapy: May be given to manage symptoms caused by excessive hormone production.

 

6. Prognosis and Survival Rate

   - Prognosis varies significantly based on tumor stage at diagnosis, with early-stage ACC having a better outlook. The 5-year survival rate is approximately:

     - Stage I–II: 50–70%

     - Stage III: Around 40%

     - Stage IV: Less than 20%

   - Recurrence is common even after successful treatment, often within 2-3 years of surgery.

 

7. Follow-Up and Monitoring

   - Post-treatment Monitoring: Regular follow-up with imaging, blood tests, and hormone level monitoring is crucial for detecting recurrence early.

   - Lifestyle Modifications: Patients may need support to manage hormone levels, diet, exercise, and mental health due to the impact of hormonal imbalance and cancer treatment.

 

8. Current Research and Advances

   Research is ongoing to improve outcomes in ACC, focusing on genetic studies to understand its causes better, targeted therapies, and novel immunotherapy approaches, which aim to enhance treatment options and extend survival.

 

Early detection and intervention are crucial in managing adrenal cortical carcinoma due to its aggressive nature. Patients with genetic predispositions or risk factors are encouraged to have regular health checks to catch any potential tumors early.